在AML中获得的多药性耐药性是由于复发性髓母细胞中低亡性原始化引起的
Elyse A Olesinski1,2, Karanpreet Singh Bhatia3, Chuqi Wang3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Blood cancer discovery
|March 5, 2024
概括
复发性急性髓性白血病 (AML) 中的多药性耐药性 (MDR) 是由亡逃避驱动的,而不仅仅是基因突变. 动态BH3分析 (DBP) 有效地识别了针对耐药AML模型的活性药物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 许多癌症的死亡率,包括急性髓性白血病 (AML),与复发与多药耐药性 (MDR) 有关.
- 研究癌症复发机制主要集中在获得的遗传突变上.
- 对向治疗的获得性耐药性在AML治疗中是一个重大挑战.
研究的目的:
- 系统地阐明复发性AML中多药耐药性 (MDR) 的基础,使用患者衍生异种移植 (PDX).
- 在复发性AML模型中识别有效的药物敏感性.
- 证明动态BH3分析 (DBP) 的可行性,用于识别抗 AML 的活性药物.
主要方法:
- 使用了22个AML患者衍生异种移植 (PDX) 模型.
- 与基因组学和转录组学一起使用动态BH3分析 (DBP) 来评估药物敏感性.
- 在体内分析获得的耐药PDX,以了解耐药机制.
主要成果:
- 发现对向药物的耐药性与具有不同机制的药物的广泛耐药性相关.
- 在经过药物选择的耐药性模型中观察到基线线粒体亡原始化的持续减少.
- 在使用DBP的耐药AML模型中确定了具有有效体内活性的特定药物.
结论:
- 逃避亡被暗示为AML多药耐药性 (MDR) 的主要驱动因素.
- 获得耐药性的保存机制涉及减少线粒体原始化和共享的转录基因签名.
- 动态BH3分析 (DBP) 是一种可行的方法,用于识别复发性多药耐药AML的患者的活性药物.
更多相关视频
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
87
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.3K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:31The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K